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Abstract
Genome-wide association studies (GWAS) in Parkinson’s disease (PD) have identified
over 20 genomic regions associated with disease risk. Many of these loci include several
candidate genes making it difficult to pinpoint the causal gene. The locus on chromosome
2q24.3 encompasses three genes: B3GALT1, STK39, and CERS6. In order to identify if the
causal variants are simple missense changes, we sequenced all 31 exons of these three
genes in 187 patients with PD. We identified 13 exonic variants including four non-synony-
mous and three insertion/deletion variants (indels). These non-synonymous variants and
rs2102808, the GWAS tag SNP, were genotyped in three independent series consisting of
a total of 1976 patients and 1596 controls. Our results show that the seven identified 2q24.3
coding variants are not independently responsible for the GWAS association signal at the
locus; however, there is a haplotype, which contains both rs2102808 and a STK39 exon 1
6bp indel variant, that is significantly associated with PD risk (Odds Ratio [OR] = 1.35, 95%
CI: 1.11–1.64, P = 0.003). This haplotype is more associated than each of the two variants
independently (OR = 1.23, P = 0.005 and 1.10, P = 0.10, respectively). Our findings suggest
that the risk variant is likely located in a non-coding region. Additional sequencing of the
locus including promoter and regulatory regions will be needed to pinpoint the association
at this locus that leads to an increased risk to PD.
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Introduction
Parkinson’s disease (PD) was not historically considered a genetic disease until in depth studies
of the segregation of genetic variants in families revealed several inherited mutations in genes
such as SNCA, LRRK2, and PARK2[1, 2]. These first discoveries were followed by population
based genome-wide association studies (GWAS) aimed at identifying risk factors for sporadic
PD, which represents up to 90% of PD cases[3]. To date, GWAS have nominated over 20 loci
influencing the risk to PD[4]. Causal genes have been nominated for a few of the loci (mostly
because they overlap with familial PD genes) but the majority of GWAS loci are defined by
large regions of linkage disequilibrium (LD) containing several different genes.
The chromosome 2q24.3 locus was associated with increased PD risk in 2011 through a
meta-analysis of GWAS published by Nalls et al[5] and has since been replicated in even larger
meta-analytical approaches [6, 7]. There has also been independent replication in Caucasian
populations although the association has not been observed in Asian series of Han Chinese
descent [8–11]. A recent GWAS in Ashkenazi Jewish patients also identified an association sig-
nal in the region, although the sample size was limited and significance was not achieved [12].
Serine Threonine Kinase 39 (STK39) has been put forward as the causal gene, but the locus, as
defined by Nalls et al, contains two other candidate genes (UDP-Gal:BetaGlcNAc Beta
1,3-Galactosyltransferase, Polypeptide 1 [B3GALT1] and Ceramide Synthase 6 [CERS6]). In
order to identify the potential causal variant(s) responsible for the GWAS signal, the region
needs to be re-sequenced and fine-mapped.
Variants in coding regions are likely to have an effect on protein structure and function and
thus a great impact on phenotype. Therefore, in the present study we undertook the screening
of all 31 exons of genes B3GALT1, STK39 and CERS6 in 187 patients with PD. We identified 13
exonic variants including four non-synonymous and three insertion/deletion variants. After
validation in controls, we genotyped the seven non-synonymous and insertion deletion vari-
ants in three independent series (US, Irish, and Polish) consisting of a total of 1976 patients
and 1596 controls. We did not identify a single variant responsible for the risk at the 2q24.3
locus but we observed a haplotype that included a STK39 coding variant which was signifi-
cantly associated with PD risk.
Materials and Methods
Study subjects
A total of 1976 patients with clinically diagnosed PD and 1596 controls were included in this
case-control study. The patients are all unrelated non-Hispanic Caucasians of European descent.
Subjects were from a US series collected at Mayo Clinic’s Florida campus (895 patients, 976
controls), an Irish series (368 patients, 368 controls), and a Polish series (713 patients, 252 con-
trols). Characteristics of subjects included in the study are summarized in Table 1 for each series.
Patients were diagnosed with PD using standard criteria[13]. Controls were individuals free of
PD or a related movement disorder at the time of examination. The Mayo Clinic Institutional
Review Board approved the study and the review boards of the Mater Misericordiae University
Hospital (Ireland), the Polish Academy of Sciences, the Medical University of Silesia, Jagiellonian
University and the Central Hospital of the Ministry of Interior and Administration (Poland)
received local IRB approvals, and all subjects provided written informed consent.
Genetic analysis
DNA was extracted from peripheral blood monocytes according to a previously described pro-
tocol.[14] In the first stage of the study (screening stage), all the exons of genes B3GALT1
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(NM_020981.3, 2 exons), STK39 (NM_013233, 18 exons), and CERS6 (NM_001256126.1, 11
exons) were sequenced in 187 patients with familial late onset PD (from the US series). This
series subset consists of 129 males (64%). These patients have a mean age of 80.4±8.1 (62–97)
years old and a mean age at onset of 65.4±8.0 (51–83) years old. Non-synonymous variants
were then validated (validation stage) by sequencing 376 control samples (168 males (45%),
mean age 67.1±12.3 (29–88)) from the US. Bi-directional sequencing was performed as previ-
ously described[14]. In addition, the three insertions/deletions in exon 1 of STK39 were geno-
typed by fragment sizing: PCR was performed using a fluorescently-labeled DNA primer,
amplicons were run on an ABI 3730XL DNA sequencer (Applied Biosystems, Foster City, CA,
USA), and reads were analyzed using GeneMapper 5 software (Life Technologies, Carlsbad,
CA, USA). For the replication stage, all samples from the US, Irish, and Polish series (including
the aforementioned 187 US PD patients and 376 US controls) were genotyped. STK39 exon 1
insertion/deletion variants (del6: ss1570217805, ins3: ss1570217817, del21: ss1570217825)
were genotyped using fragment sizing as previously described and the other identified variants
(rs141683896, rs56031549, rs4496303, rs34110122) as well as GWAS tag rs2102808 were geno-
typed using TaqMan Allelic Discrimination Assays on an ABI 7900HT Fast Real-Time PCR
system (Applied Biosystems, Foster City, CA, USA) and data was analyzed using Taqman Gen-
otyper Software Version 1.3 (Applied Biosystems, Foster City, CA, USA). Primer sequences
and amplification conditions are available upon request. Call rate for sequencing and genotyp-
ing was98% at each stage.
Statistical analysis
For stage 2 (validation), chi-square tests were used to compare the frequency of each variant
between the 187 PD patients and 376 controls included in that stage. For stage 3 (replication),
the association of each variant with PD was evaluated using a logistic regression model. ORs
and 95% confidence intervals (CIs) were estimated, and each variant was considered under an
additive model (i.e. effect of each additional minor allele). Additionally, to evaluate the effect of
the coding single nucleotide polymorphisms (SNPs) on the GWAS association signal, we
adjusted for each coding SNP individually and together in logistic regression models that
included rs2102808 as a covariate (under an additive model). To test the combined effect of
alleles, haplotype-based logistic regression analyses were performed on the variants with minor
allele frequency (MAF)>1%, where only haplotypes occurring at a frequency of 1% or greater
were considered. All regression models were adjusted for age, gender, and series (combined
Table 1. Patient characteristics.
Series N Age Age at onset No. Male (%)
USA
Cases 895 76.1±11.8 (35–104) 62.8±12.2 (16–94) 567 (63.4)
Controls 976 72.1±13.3 (25–98) 418 (42.8)
Ireland
Cases 368 62.7±10.4 (32–87) 55.6±12.1 (18–87) 205 (55.7)
Controls 368 66.0±22.3 (17–97) 136 (37.0)
Poland
Cases 713 67.0±12.1 (17–101) 56.8±11.9 (23–92) 433 (60.7)
Controls 252 57.7±15.7 (19–96) 143 (56.7)
The sample mean ± SD (minimum-maximum) is given for age and age at onset.
doi:10.1371/journal.pone.0128586.t001
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series only). Where indicated (P corr) P-values were corrected using the Bonferroni correction.
P-values of 0.05 or lower were considered as statistically significant. All analyses were per-
formed using PLINK v1.7 (http://pngu.mgh.harvard.edu/purcell/plink/)[15].
Result
We aimed to explain the PD GWAS signal at the chromosome 2q24.3 locus. In order to detect
putative causal PD risk variants, we sequenced all 31 exons of genes B3GALT1, STK39, and
CERS6 in 187 PD cases from our US series. Upon sequencing of exon 1 of gene STK39, we
identified a region rich in repeats and containing three in frame indels, an insertion of three
base pairs, a deletion of six base pairs and a deletion of 21 base pairs (see Fig 1). We comple-
mented our sequencing with fragment sizing to fully genotype these exon 1 variants. Following
this screening, we identified 13 variants including four non-synonymous changes and three
indels (Table 2). One non-synonymous SNP was located in B3GALT1 (exon 2), three indels
(exon 1) and one non-synonymous SNP (exon 11) were located in STK39, and two non-synon-
ymous SNPs were located in CERS6 (exon 1 and 5).
We prioritized the non-synonymous and indel variants as they are more likely to have a
functional impact. To validate the non-synonymous variants identified, we sequenced (and
genotyped through fragment sizing) 376 controls from our US series. Although none of the
variants were statistically significant when comparing frequencies with the aforementioned 187
PD cases (Table 2), odds ratio estimates in this small patient-control group suggested that
some may increase risk of PD. After evaluation of our statistical power to detect a significant
association signal in our replication cohort, we decided to follow up on all non-synonymous
variants.
In order to assess the role of our coding SNPs in PD risk at this locus, we genotyped all
seven variants in all 1976 patients and 1596 controls from each of our three series (US, Irish,
and Polish) and compared the association signal with GWAS locus tag SNP rs2102808 (chro-
mosome 2 position 169117025 assembly GRCh37.p13). Fluorescent-based PCR fragment siz-
ing of the indels allowed phasing of the three variants. Four alleles exist at the locus, they are:
wt-wt-wt (70.3%), del6-wt-wt (20.9%), del6-wt-del21 (6.44%), and wt-ins3-wt (2.36%). The
wt-ins3-wt allele sits on a haplotype with rs2102808 allele G (protective) and the del21 allele is
more frequently transmitted with rs2102808 allele T (risk allele). The linkage disequilibrium
between the four STK39 SNPs and rs2102808 is presented in S1 Fig.
Fig 1. STK39 exon 1 insertion/deletion variants.We detected three insertion/deletion (indels) variants in exon 1 of gene STK39. The indels are located in a
proline/alanine rich protein domain called the PAPA box. The figure was created using the UCSC genome browser. (http://genome.ucsc.edu/)
doi:10.1371/journal.pone.0128586.g001
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The results of the single variant association tests are shown in Table 3. The STK39 ins3 vari-
ant consisting of an in frame insertion of three base pairs in a repeat region of exon 1 shows
association with risk of PD in the US series (OR: 1.59, 95% CI: 1.01–2.51, P = 0.046), before
correction for multiple testing, but this was not seen in the other series, including the large
combined series (OR: 1.27, 95% CI: 0.91–1.75, P = 0.16). This is possibly due to population het-
erogeneity. The only SNP that was significantly associated with PD in the combined patient-
control series was the GWAS tag SNP rs2102808 (OR: 1.23, 95% CI: 1.06–1.42, P = 0.005, P
corr = 0.04). Additionally, in logistic regression analyses adjusting for the 2q24.3 locus coding
variants, the GWAS association signal for rs2102808 was not altered (data not shown).
We were interested in testing if haplotypes consisting of the GWAS SNP and the 2q24.3
coding SNPs carried increased risk to PD compared to single variants. Results for the three
series are shown in Table 4. One haplotype defined by the rs2102808 minor allele (G>T) and a
six base pair insertion in exon 1 of STK39 (del6, CGGGGC>-) was significantly associated
with PD in the combined series (OR = 1.35, 95% CI: 1.11–1.64, P = 0.003, P corr = 0.02). This
particular haplotype is more significantly associated than rs2102808 by itself in the combined
series (P corr = 0.04) and the OR suggests that it confers a slightly increased risk to PD than the
GWAS variant (1.35 (1.11–1.64) compared to 1.23 (1.06–1.42)).
Table 2. Exonic variants detected by sequencing of 187 PD patients and validation in 376 controls.
Gene Exon Position on
Chr2
(GRCh37)
rs/name base change AA
change
MAF in
Cases
(%)
Allele
counts
in Cases
MAF in
Controls
(%)
Allele
counts in
Controls
OR
(95%
CI)
P
B3GALT1 1* 168675188 rs836722 C>T 19.84 65/303
B3GALT1 1* 168675206 rs836723 C>T 19.84 65/303
B3GALT1 2 168725616 T>C L23L 0.27 1/371
B3GALT1 2 168725741 rs141683896 A>T E64D 0.53 2/372 0.28 2/724 1.95
(0.27–
13.87)
0.50
STK39 11 168931636 rs56031549 C>T A399T 1.10 4/360 0.41 3/723 2.68
(0.60–
12.03)
0.18
STK39 3 169023879 G>A N120N 0.27 1/371
STK39 1 169103798 del6 CCGGGG>- deletion
PA
30.48 114/260 27.93 210/542 1.13
(0.86–
1.49)
0.37
STK39 1 169103868 ins3 ->CGC insertion A 2.14 8/366 1.33 10/742 1.62
(0.63–
4.14)
0.31
STK39 1 169103872 del21 GCCGCCGCCGCTGTCACCGGG>- deletion
AAAATVP
7.22 27/347 5.05 38/714 1.46
(0.88–
2.43)
0.14
CERS6 1 169312974 rs4496303 G>A A6T 0.81 3/367 0.95 7/731 0.85
(0.22–
3.32)
0.82
CERS6 5 169547547 rs34110122 C>T P157S 0.27 1/373 0.14 1/729 1.95
(0.12–
31.33)
0.63
CERS6 7 169571519 rs116506340 C>T G206G 0.80 3/371
CERS6 8 169574432 G>A L263L 0.27 1/371
*Exon 1 of B3GALT1 is non-coding, AA = amino acid, MAF = minor allele frequency, OR = Odds ratio, CI = confidence interval, P = P-value. Only non-
synonymous and indel coding variants were genotyped in controls.
doi:10.1371/journal.pone.0128586.t002
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Discussion
Our screening at the PD GWAS locus at 2q24.3 identified a risk haplotype defined by
rs2102808 allele T as well as a six base pair deletion in exon 1 of the STK39 gene. This
Table 3. Single variant associations with PD.
A. US series (895 patients, 976 controls)*
Variant MAF in cases (%) Allele counts in cases MAF in controls (%) allele counts in controls OR (95% CI) P P corr
rs141683896 0.17 3/1753 0.21 4/1930 0.86 (0.19–4.03) 0.85 1
rs56031549 1.29 23/1757 0.97 19/1933 1.43 (0.76–2.69) 0.27 1
del6 27.71 491/1281 26.52 516/1430 1.08 (0.93–1.25) 0.34 1
ins3 2.71 48/1726 1.8 35/1911 1.59 (1.01–2.51) 0.05 0.37
del21 5.64 100/1674 4.93 96/1850 1.17 (0.87–1.57) 0.29 1
rs2102808 14.74 263/1521 12.35 241/1711 1.3 (1.07–1.58) 0.009 0.07
rs4496303 1.19 21/1751 1.57 30/1882 0.67 (0.38–1.2) 0.18 1
rs34110122 0.11 2/1754 0.21 4/1924 0.44 (0.08–2.53) 0.36 1
B. Irish series (368 patients, 368 controls)*
Variant MAF in cases (%) Allele counts in cases MAF in controls (%) allele counts in controls OR (95% CI) P P corr
rs141683896 0.55 4/718 0.69 5/715 0.73 (0.19–2.8) 0.65 1
rs56031549 1.11 8/712 2.07 15/709 0.47 (0.19–1.16) 0.1 0.82
del6 26.67 192/528 24.72 179/545 1.08 (0.84–1.38) 0.54 1
ins3 2.64 19/701 2.9 21/703 0.83 (0.43–1.61) 0.59 1
del21 8.89 64/656 6.91 50/674 1.24 (0.84–1.82) 0.27 1
rs2102808 15.16 111/621 13.04 96/640 1.14 (0.85–1.53) 0.39 1
rs4496303 1.54 11/705 1.12 8/708 1.33 (0.52–3.4) 0.56 1
rs34110122 0.28 2/706 0.84 6/712 0.37 (0.07–1.88) 0.23 1
C. Polish series (713 patients, 252 controls)*
Variant MAF in cases (%) Allele counts in cases MAF in controls (%) allele counts in controls OR (95% CI) P P corr
rs141683896 0.14 2/1386 0.2 1/503 0.35 (0.03–4.2) 0.41 1
rs56031549 1.35 19/1391 0.41 2/488 3.6 (0.81–15.97) 0.09 0.73
del6 30.01 404/942 27.33 135/359 1.17 (0.92–1.48) 0.21 1
ins3 2.23 30/1316 2.43 12/482 0.98 (0.5–1.9) 0.94 1
del21 7.5 101/1245 8.1 40/454 0.96 (0.65–1.42) 0.85 1
rs2102808 14.89 207/1183 13.35 67/435 1.24 (0.89–1.71) 0.2 1
rs4496303 1.03 14/1342 1.81 9/489 0.51 (0.22–1.19) 0.12 0.95
rs34110122 0.22 3/1335 0 0/504 NA 1 1
D. Combined series (1976 patients, 1596 controls)*
Variant MAF in cases (%) Allele counts in cases MAF in controls (%) allele counts in controls OR (95% CI) P P corr
rs141683896 0.23 9/3857 0.32 10/3148 0.81 (0.31–2.12) 0.67 1
rs56031549 1.28 50/3860 1.14 36/3130 1.18 (0.75–1.86) 0.47 1
del6 28.32 1087/2751 26.23 830/2334 1.1 (0.98–1.22) 0.1 0.83
ins3 2.53 97/3743 2.15 68/3096 1.27 (0.91–1.75) 0.16 1
del21 6.9 265/3575 5.88 186/2978 1.13 (0.93–1.38) 0.22 1
rs2102808 14.87 581/3325 12.66 404/2786 1.23 (1.06–1.42) 0.005 0.04
rs4496303 1.2 46/3798 1.5 47/3079 0.76 (0.5–1.16) 0.2 1
rs34110122 0.18 7/3795 0.32 10/3148 0.64 (0.24–1.75) 0.39 1
MAF = minor allele frequency, OR = Odds ratio, CI = confidence interval, P = p-value, P corr = p-value with Bonferroni correction. ORs, 95% CIs, and P-
values result from logistic regression models adjusted for age, gender, and series (combined series only).
*Numbers of samples with complete clinical information included in model.
doi:10.1371/journal.pone.0128586.t003
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haplotype is associated with an increased risk of PD (p = 0.003, OR = 1.35) with an estimated
effect size that is greater than the effect observed when these alleles are tested independently
(OR = 1.1 [del6] and 1.23 [rs2102808]). Given that the strength of the association is greater for
this haplotype than for each single allele individually (p = 0.10 and 0.005), it is possible to sus-
pect a contribution of the del6, or an untested variant in LD with it, to PD, although with a
small effect size.
Our screening did not identify a single common coding variant responsible for the locus
association signal which suggests at least two scenarios: 1) the causal risk factor at the locus
consists of several different variants of low frequency and our sample size is too small to detect
individual effects, or 2) the causal variant is located outside of the coding region. In the latter
Table 4. Haplotypic associations with PD.
A. US series (895 patients, 976 controls)*
Haplotype (rs56031549, del6, ins3, del21, rs2102808, rs4496303) MAF in cases (%) MAF in controls (%) OR P P corr
111112 0.96 1.25 0.68 (0.34–1.34) 0.26 1
121221 5.3 4.62 1.17 (0.86–1.58) 0.31 1
121121 8.59 6.71 1.4 (1.09–1.8) 0.009 0.06
112111 2.64 1.74 1.63 (1.02–2.61) 0.04 0.25
122111 12.93 14.42 0.86 (0.71–1.04) 0.11 0.66
111111 69.58 71.27 0.91 (0.78–1.05) 0.18 1
B. Irish series (368 patients, 368 controls)*
Haplotype (rs56031549, del6, ins3, del21, rs2102808, rs4496303) MAF in cases (%) MAF in controls (%) OR P P corr
111112 1.19 0.68 1.86 (0.55–6.28) 0.32 1
121221 6.96 5.69 1.18 (0.77–1.81) 0.45 1
121121 6.99 5.58 1.23 (0.81–1.88) 0.34 1
112111 2.67 2.74 0.91 (0.47–1.78) 0.79 1
122111 10.05 10.86 0.92 (0.65–1.32) 0.66 1
111111 69.67 72.07 0.93 (0.73–1.18) 0.54 1
C. Polish series (713 patients, 252 controls)*
Haplotype (rs56031549, del6, ins3, del21, rs2102808, rs4496303) MAF in cases (%) MAF in controls (%) OR P P corr
111112 1.03 1.87 0.46 (0.2–1.09) 0.08 0.46
121221 6.85 7.4 0.97 (0.64–1.46) 0.87 1
121121 7.17 5.11 1.45 (0.9–2.34) 0.13 0.78
112111 2.2 2.22 1.07 (0.55–2.08) 0.84 1
122111 14.97 14.39 1.05 (0.78–1.41) 0.75 1
111111 67.78 69 0.93 (0.74–1.17) 0.53 1
D. Combined series (1976 patients, 1596 controls)*
Haplotype (rs56031549, del6, ins3, del21, rs2102808, rs4496303) MAF in cases (%) MAF in controls (%) OR P P corr
111112 1.03 1.26 0.74 (0.46–1.21) 0.23 1
121221 6.15 5.33 1.1 (0.9–1.35) 0.36 1
121121 7.86 6.27 1.35 (1.11–1.64) 0.003 0.02
112111 2.52 2.1 1.3 (0.93–1.81) 0.12 0.71
122111 13.19 13.66 0.92 (0.8–1.06) 0.27 1
111111 69.24 71.39 0.91 (0.82–1.02) 0.1 0.57
Haplotypes are encoded as 1 for major allele and 2 for minor allele see Table 2 for specific alleles, MAF = minor allele frequency, OR = Odds ratio,
CI = confidence interval, P = p-value, P corr = P-value with Bonferroni correction. ORs, 95% CIs, and P-values result from haplotype-based logistic
regression analysis.
*Numbers of samples with complete clinical information included in model.
doi:10.1371/journal.pone.0128586.t004
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case, a screening of the non-coding regions might identify variants located in regulatory ele-
ments such as promoter and enhancers that modulates gene expression levels. Of interest
for the study of PD, BioGPS reports STK39mRNA levels to be greatest in brain regions com-
pared to other tissue tested with the affymetrix expression microarray U133, whereas CERS6
mRNA levels are higher in dendritic cells and in the pineal gland and B3GALT1 is expressed
ubiquitously[16]. Protein STK39 is a kinase involved in the phosphorylation and activation of
Na+-K+-Cl- co-transporters. These transporters are implicated in the neuronal depolarizing
response led by GABA and glycine neurotransmitters via changes in the intracellular concen-
tration of Cl-. [17] STK39 knockout mice have been shown to have higher nociceptive thresh-
old, impaired motor function and increased anxiety [18].
Although no conclusions can be drawn as to the location of the causal variants based on this
particular study, the STK39 exon 1 is an interesting candidate region in the search for regula-
tory variants, as it contains many repeat elements. The exon encodes a proline/alanine rich
region (amino acids 12 to 53) called the PAPA box for which the precise function is still
unknown[17]. The PAPA box is designated as an active promoter region and includes a CTCF
binding site based on ENCODE ChIP-seq data[19]. CTCF is a ubiquitously expressed protein
which functions as transcriptional repressor, activator or an insulator blocking enhancer activ-
ity and thus influencing gene expression[20]. We identified three indels located in the PAPA
box but none of these variants were significantly associated with PD risk. The variant located
on the associated haplotype is a two amino acid deletion with a minor allele frequency of
~26%. The variant is located in a repeat motif (unit: CGGGGC) with the major allele being five
repeat units and the minor four.
Resolving the underlying genetic variation at each GWAS loci that is associated with disease
susceptibility is critical to our understanding of not only the clinical relevance but also the dis-
ease mechanisms. This goal is challenging and even for the loci that overlap with known famil-
ial PD genes (e.g. SNCA and LRRK2), the functional associated variants accounting for the
GWAS signal have not yet been identified. The exonic portion of the LRRK2 gene, recognized
as the most common genetic cause of both familial and sporadic PD, has been extensively stud-
ied by our group [21]. Although low penetrant variants have been identified and confirmed to
modestly increase or decrease disease risk, these associations do not explain the GWAS signal
at the LRRK2 locus [22]. This most likely reflects the presence of functional/regulatory variants
located outside of the coding region accounting for the association signal. This is also the case
for the SNCA gene with no common coding variation observed, and may be a common phe-
nomenon for a number of the other GWAS nominated loci. If this is true, additional genetic
sequencing studies with increased sample size and a focus extended to non-coding regulatory
regions will be needed to pinpoint to the precise variants responsible for the association signal
at locus Chromosome 2q24.3.
Supporting Information
S1 Fig. Linkage disequilibrium (LD) between chromosome 2q24.3 variants. Left panel (A)
shows the D’ values and right panel the r2 values. The LD was calculated in the US control
samples and the figure was created using Haploview (Barrett JC, Fry B, Maller J, Daly MJ. Hap-
loview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005 Jan 15). A.
Numbers on the squares represent D’(x100) between two variants, no number mean D’ = 1. A
white square represents LOD scores less than 2 and D’ less than 1 (low LD), a light blue square
represents D’ = 1 but LOD score less than 2. Shades of pink squares represent D’ less than 1
and LOD score more than 2 and bright red squares show variant in LD, D’ = 1 and LOD score
more than 2. B. Shades of grey squares represent the correlation between variants expressed as
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r2 (x100). Del6, del 21 and rs2102808 are in high LD but have very different minor allele fre-
quencies, hence the high D’ and low r2.
(PDF)
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